

2026 INVESTOR DAY



Disclaimer

In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by Diasorin S.p.A. (“Diasorin” or the “Company” and, together with its subsidiary the “Group”). The Presentation is being furnished to you for information purposes only and for use in presentations of the industrial plan of the Group.

No distribution of this Presentation. This Presentation is being furnished to you solely for your information and may not be reproduced, in whole or in part, or redistributed to any other individual or legal entity.

Verbal explanation. This Presentation has to be accompanied by a verbal explanation. A simple reading of this Presentation without the appropriate verbal explanation could give rise to a partial or incorrect understanding.

No offer to purchase or sell securities. The information, statements and opinions contained in this Presentation are for information purposes only and do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of an offer to purchase or subscribe for securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

Rounding. Due to rounding, numbers presented throughout this Presentation may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Miscellanea. This Presentation has been prepared on a voluntary basis. Diasorin is therefore not bound to prepare similar presentations in the future, unless where provided by law. Neither the Company nor any member of the Group nor any of its or their respective representatives, directors, employees or agents accept any liability whatsoever in connection with this Presentation or any of its contents or in relation to any loss arising from its use or from any reliance placed upon it.

Teresa Cervino, the manager responsible for the preparation of the company accounting documents for Diasorin S.p.A., declares that, pursuant to Article 154-bis, paragraph 2, of the Legislative Decree February 24, 1998, no. 58, to the best of his knowledge, the accounting information included in this Presentation correspond to document results, books and accounting records.

Forward-looking statements

This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Diasorin may make forward-looking statements orally to analysts, investors, representatives of the media and others. In particular, among other statements, certain statements regarding future financial performance, the achievement of certain targeted metrics at any future date or for any future period, trends in results of operations, margins, costs, return on capital, risk management and competition are forward-looking in nature. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, or similar terms. Forward-looking statements are not guarantees of future performance and are, by their nature, subject to inherent risks, uncertainties and assumptions that are difficult to predict because they relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them.

Forward-looking statements do not take into account any additional effects that may arise from impacts on the global market in which Diasorin operates and, more generally, on the macroeconomic scenario.

Actual results may differ materially from those expressed in forward-looking statements as a result of a variety of factors, including: changes in the global financial markets, general economic environment and changes in demand for diagnostic/healthcare/life sciences products, which is subject to cyclicalities; changes in local economic and political conditions, changes in trade policy and the imposition of global and regional tariffs or tariffs targeted to the diagnostic/healthcare/life sciences industry, the enactment of tax reforms or other changes in tax laws and regulations; the Group’s ability to offer innovative, attractive products; various types of claims, lawsuits, governmental investigations and other contingencies, including product liability and warranty claims, investigations and lawsuits; material operating expenditures in relation to compliance with health and safety regulations; the intense level of competition in the diagnostic/healthcare/life sciences industry, which may increase due to consolidation; the Group’s ability to fund its defined benefit pension plans; the ability to access funding to execute its business plans and improve its own businesses, financial condition and results of operations; the Group’s ability to realize anticipated benefits from joint venture arrangements; disruptions arising from political, social and economic instability; commercial risk due to the fact that the Group operates in a market characterized by the presence of large competitors; risk associated to the maintenance of relationship with customers and strategic partners; risks associated with relationships with employees and suppliers; increases in costs, disruptions of supply or shortages of raw materials; developments in labor and industrial relations and developments in applicable labor laws; exchange rate fluctuations, interest rate changes, credit risk and other market risks; political and civil unrest; earthquakes or other disasters.

Any forward-looking statements contained in this document speak only as of the date of this document and Diasorin disclaims any obligation to update or revise publicly forward-looking statements. Further information concerning the Group and its business, including factors that could materially affect the Group’s financial results, are included in Diasorin’s reports and filings with CONSOB and Borsa Italiana.

No update. The information and opinions in this document is provided to you as of the dates indicated and Diasorin does not undertake to update the information contained in this document and/or any opinions expressed relating thereto after its presentation, even in the event that the information becomes materially inaccurate, except as otherwise required by applicable laws.

Non-IFRS and Other Performance Measures. This document contains certain items as part of the financial disclosure, which are not defined under IFRS. Accordingly, these items do not have standardized meanings and may not be directly comparable to similarly-titled items adopted by other entities. Diasorin management has identified a number of “Alternative Performance Indicators” (“APIs”). These APIs (i) are derived from historical results of Diasorin and are not intended to be indicative of future performance, (ii) are non-IFRS financial measures and, although derived from the financial statements, are unaudited and (iii) are not an alternative to financial measures prepared in accordance with IFRS. The APIs presented herein include EBIT¹, EBITDA², adjusted EBITDA³, Net Financial Position⁴ and Free Cash Flow⁵. These measures are not indicative of historical operating results, nor are they meant to be predictive of future results. These measures are used by the management to monitor the underlying performance of the business and operations. Similarly entitled non-IFRS financial measures reported by other companies may not be calculated in an identical manner, consequently the measures reported in this document may not be consistent with similar measures used by other companies. Therefore, investors should not place undue reliance on this data.

¹ EBIT is defined as the “Operating Result” net of interests and taxes – ² EBITDA is defined as the “Operating Result”, gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group’s operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group’s operating result performance. - ³ Adjusted EBITDA is defined as Adjusted EBITDA, excluding extraordinary costs and expenses incurred in the Luminex transaction announced on April 11, 2021 - ⁴ The Net Financial Position is defined as the algebraic sum (positive balance sheet assets and negative balance sheet liabilities) of cash and cash equivalents and other current financial assets, minus current financial liabilities and non-current financial liabilities. - ⁵ Free Cash Flow is defined as the set of means available to the Company and is equal to cash flows deriving from operating activities net of interest received or paid, and net of investments and divestments of fixed assets.

01 WELCOME

Michele Denegri
Chairman



Diasorin

The Diagnostic Specialist

Agenda

Strategic Overview

Immunodiagnosics

Molecular Diagnostics

Licensed Technologies

ESG & Financials

Key Takeaways

Q&A

02

STRATEGIC OVERVIEW

Carlo Rosa

CEO

We have achieved significant progress since our last Investor Day

Expanded our presence in the U.S. market

40% of global IVD market

Gained access to a unique multiplexing asset,

broadening our molecular offering and reinforcing our differentiated positioning

Strengthened access to U.S. hospitals supporting a successful Group strategy

while enhancing our market positioning alongside the immunodiagnostics franchise

Created new business development opportunities in Life Science,

expanding our reach among academic and biopharma customers

TODAY

U.S. accounts for
~50% of our
Total Revenue

Molecular is our
strongest growth
engine

Immunodiagnostics
supporting steady
growth

LTG is a critical
enabler for innovation
and growth

IVD Market at a glance

The In Vitro Diagnostics (IVD) market remains one of the most dynamic and resilient segments within global healthcare. Following significant expansion during the COVID-19 pandemic, the global IVD market is now undergoing a period of normalization.

Excluding COVID-related revenues, the market has stabilized at an estimated value of approximately 60 \$/bn, while maintaining a solid long-term growth trajectory and gradually returning to pre-pandemic growth trends.

70-80 \$/bn

Global IVD
Market Size
during COVID

Total addressable market across immunoassay, molecular diagnostics, and point-of-care testing.

~60 \$/bn

Normalized
Post-COVID
Baseline

Structural market value excluding COVID-19 testing tailwinds, confirming underlying market resilience.

+3%

Growth
trajectory intact

Recovery toward pre-pandemic trends

Fragmented landscape

Top 5 players hold ~65% share; no single dominant player

Diasorin positioning

Specialist player at intersection of fastest-growing IVD segments

5 Macro Trends in Healthcare reshaping Diagnostics

5 macro forces reshaping diagnostics
through 2030



Demographic shift

Aging populations & chronic disease burden



Consolidation in the Core Labs

High-throughput automation & workflow integration



Decentralization

Lab to Point-Of-Care migration



Value-Based Care

Healthcare spending pressure & Value-Based reimbursement



Precision Medicine and Complementary Diagnostics

Personalized, targeted diagnostics

5 Macro Trends in Healthcare reshaping Diagnostics



Demographic shift

Aging populations & chronic disease burden

1 in 6 people globally over 60 by 2030
(Source: WHO)

In Diasorin's core markets, 65+ cohort
growing at 2-3x general population

Multi-morbidity patients generate 4-6x
diagnostic utilization vs. healthy adults

Driving specialty testing growth in
autoimmune, hypertension, and IBD/IBS



Consolidation in the Core Labs

High-throughput automation & workflow integration

Hospital labs under pressure: 15%
vacancy rate (EU clinical labs)

Rising testing volumes and cost-per-test
targets

Automation platforms reducing hands-on
time, enabling 24/7 operation



Decentralization

Lab to Point-Of-Care migration

Significant diagnostic testing volume will
migrate outside central hospital labs by
2030, including respiratory testing and
women's health

5 Macro Trends in Healthcare reshaping Diagnostics



Value-Based Care

Healthcare spending pressure & Value-Based reimbursement

Reimbursement reform is driving a shift toward lower prices, higher clinical evidence requirements, and greater scrutiny of laboratory spending

Regional Dynamics

United States

PAMA recalibration reduced Medicare rates 10-15%; payers tightening multiplex respiratory panel authorizations

Europe

German EBM reform cutting immunoassay reimbursement 8-12%; volume caps in France/Italy

China

VBP Round 5 included immunoassay reagents at 45% discounts; NMPA compliance costs rising



Precision Medicine and Complementary Diagnostics (CDx)

Personalized, targeted diagnostics

60 new biological drugs expected by 2030 requiring complementary diagnostic tools

Regulatory requirement: CDx demanded by payers and regulators to stratify patient populations

Diasorin is well positioned to address key sector trends



DEMOGRAPHIC SHIFT

- ✗ Cancer
- ✗ Alzheimer
- ✗ Diabetes

- ✓ Autoimmunity
- ✓ IBD/IBS
- ✓ Hypertension



CONSOLIDATION

- ✓ NEW LIAISON XL 

- ✓ AutoX 
- ✓ DiluteX

- ✓ Connectivity to every TLA platform 



DECENTRALIZATION

- ✓ LIAISON NES 

- ✓ Respiratory
- ✓ Women's health



VALUE-BASED CARE

- ✓ LIAISON PLEX 
- ✓ Flex panels

- ✓ Calprotectin HD 



PRECISION MEDICINE AND COMPLEMENTARY DIAGNOSTICS

Focus on new classes of drugs in

- 
- ✓ IBD

- 
- ✓ Hypertension

IVD players divided in 2 groups

Multi-segment driven by Total Lab Automation (TLA)

- Immunoassay
- Clinical Chemistry
- LC-Mass-Spec
- Haematology
- High-Throughput Molecular Testing



Clinically specialized across technologies with leadership positions

Bacteriology and Microbiology



Coagulation



Transplant



Onco-Haematology



Diasorin unique positioning: what does it mean to be a Specialist in diagnostics today

Diasorin stands as a unique company because:

- It doesn't play in a unique clinical specialty area but **in all areas where specialty assays are needed**
- It is **flexible** to competitive pressure and new emerging clinical opportunities

EXAMPLES

INFECTIOUS DISEASES

H. Pylori Ag, MeMed, *C. auris* PCR, HSV (spinal fluid) PCR

ENDOCRINOLOGY

1,25 Vitamin D, Renin / Aldosterone, TRAb «next generation»

IBD/IBS

Calprotectin / Elastase



Leader in Specialty
Diagnostics



Trusted LIAISON
Brand



High Exposure to
U.S. Market



Large Global
Installed Base

Diasorin's Unique Specialist Positioning

An integrated Specialty Portfolio built around high-value indications, targeted settings, and clinical workflow fit

Immunodiagnosics

Leads in specialty, high-value clinical indications

- ✓ Extensive Specialty Menu (>130 CLIA tests, broadest specialty menu worldwide)
- ✓ Fully Automated Platform (LIAISON XL + LAS)
- ✓ Suited for laboratories of all sizes
- ✓ Market leader in clinical areas (Infectious Disease, Bone & Mineral, Endocrinology, Renal Metabolism, Gastrointestinal)

Molecular Diagnostics

Wins where speed, flexibility and ease of use matter most

- ✓ Growing Specialty Low-Plex Assay Menu (Targeted specialties)
- ✓ Flexible Multiplexing Platform (FLEX feature on LIAISON PLEX)
- ✓ Decentralized Testing Capability (LIAISON NES POC platform)

Licensed Technologies

Enables innovation for strategic partners

- ✓ Strategic Partner Access in specialty diagnostic areas (Transplant, Autoimmunity)
- ✓ Life Science / Biopharma Exposure provides access to innovation by large partners

Looking Forward to 2030: what do we commit to deliver

Immunodiagnosics

>20 new specialty assays

New LIAISON XL for high-throughput customers

TB market leadership

Launch of 1 Companion Diagnostic product

Molecular Diagnostics

Increasing competitiveness of LIAISON NES

Complete panel portfolio on LIAISON PLEX

New LIAISON MDX Plus to support our specialty portfolio

Licensed Technologies

New contracts with Diagnostic and Biopharma partners

Stabilization of sales to customers linked to Academia

Scalable licensing, royalties and long-term recurring revenue streams


03

IMMUNODIAGNOSTICS

Chen Even

CCO

Immunology Market Size and Clinical Areas



GLOBAL MARKET - IMMUNOASSAYS

~18 €/bn

- Focus Clinical areas for Diasorin
- Future areas of development
- Clinical areas not served by Diasorin


Sources: Diasorin sales data, Diasorin internal market research, GDMS data, Markets & Markets Immunodiagnosics forecast to 2030 report, DHC

**Diasorin serves with strategic focus roughly 40% of the market
Future opportunities in one specific segment (autoimmunity)**


Broadening the distance to competition





Differentiating & High-Volume Specialties



High-routine tests



-  Diasorin Immunoassay tests
-  Tests of the main competitor within the area

“ We have the broadest immunoassay menu available on the market ”

PRODUCTS


Latent Tuberculosis



Latent Tuberculosis - Market



Tuberculosis



Active TB

- > 10 million active cases globally
- Symptomatic and contagious
- Often deadly if not treated

Characteristics

- TB is actively spreading
- Testing through NAAT, chest X-Ray, sputum culture

Latent TB

- ~2 billion latent infections globally
- Asymptomatic and not contagious
- 10% of infected will develop active TB

Characteristics

- Hard to identify
- Testing through skin or IGRA tests (QuantiFERON – market leading test)

~2 bn

People infected with latent TB

>75 mln

latent TB tests annually

>45 mln

skin tests to be converted to QFT

1.6 \$/bn

latent TB testing TAM in 2026

TUBERCULOSIS IS THE WORLD'S DEADLIEST INFECTIOUS DISEASE

Source: QIAGEN and Diasorin

Latent Tuberculosis – Full automation and improved efficiency



Advancing workflow automation

Inpeco partnership
move QuantiFERON
and LIAISON
towards a full
ecosystem solution



Addressing the need to **improve pre-analytical steps in labs**

QIAGEN **fully automates** the process with Inpeco and Diasorin partnerships


Process automation can be adapted to **specific customer needs**

Ambition to be the first FDA-approved, CE-marked **fully automated TB test**

LIAISON QuantiFERON-TB Gold Plus II assay delivering **25% faster turnaround time** and enabling testing of **~75% more patients/hour**




Source: QIAGEN and Diasorin



Our competitive advantage



Tubes for **CD4** and **CD8** antigen testing



Market leader in TB segment



QFT-TB brand recognized as **WHO Gold-Standard**



Broadest claims for patient population

COMPETITIVE ADVANTAGES TO FACE POTENTIAL COMPETITION ON TB

Gastrointestinal



GI Health: Serving Dx Needs for Gastroenterologists



BACTERIAL

- 🔍 Simplexa® *C. difficile* Direct Kit
- 🔍 LIAISON® *C. difficile* GDH
- 🔍 LIAISON® *C. difficile* Toxins A&B
- 🔍 LIAISON® Campylobacter Ag
- 🔍 LIAISON® Meridian *H. pylori*
- 🔍 LIAISON® *H. pylori* IgG
- 🔍 LIAISON® Legionella Urinary Ag
- 🔍 LIAISON® PLEX GI Flex



VIRAL

- 🔍 NxTAG® Gastrointestinal Pathogen Panel*
- 🔍 LIAISON® PLEX GI Flex
- 🔍 LIAISON® Adenovirus
- 🔍 LIAISON® Rotavirus

MELABSORPTION

- 🔍 LIAISON® Elastase-1
- 🔍 LIAISON® tTG IgA

MELABSORPTION

- 🔍 LIAISON® Elastase-1
- 🔍 LIAISON® tTG IgA

PRE-TREATMENT INFECTIOUS SCREENING

- 🔍 LIAISON® QuantiFERON-TB Gold Plus II
- 🔍 LIAISON® Cytomegalovirus (CMV) Diagnostic Solution
- 🔍 LIAISON® EBV Diagnostic Solution
- 🔍 LIAISON® Hepatitis Diagnostic Solution

■ SERUM/PLASMA SAMPLE
 ■ STOOL SAMPLE
 ■ URINE SAMPLE

🧬 MOLECULAR ASSAYS
 🧪 IMMUNOASSAYS

Diasorin GI Immunodiagnosics Panel

BROAD, INTEGRATED GI MENU (8 LIAISON TESTS)

- Covers **inflammation, infectious diseases, pancreatic markers, and celiac**
- Drives both clinical value and sustainable growth, from GI diagnostics to an **integrated, patient-centric GI management ecosystem**
- **Strengthens clinical depth** and competitive differentiation
- **Unique system-level** advantage
- **Enables management of related conditions** through broad adjacent menu



NEAR-TERM INNOVATION AND NEXT-WAVE PIPELINE (2026-2027)

- **LIAISON Q.S.E.T. Quick Pick – home stool collection kit:**
 - reduces lab workload
 - improves sample quality
 - enhances patient convenience

- **LIAISON Calprotectin HD**
- **LIAISON Lactoferrin**
- **LIAISON FOB**
- **LIAISON expanded Celiac panel**



One-platform solution for diagnosis + monitoring across GI diseases

Calprotectin – Market overview

5-10% of the world population has **IBS**

~1% of the **western world population** has **IBD**

10% of all **primary care visits** are due to **GI symptoms**

Calprotectin is the key test to distinguish IBS vs. IBD and to monitor inflammation

Rising prevalence of chronic GI diseases (IBD, IBS), with increasing burden of gastrointestinal infections

→ **Sustained demand growth for non-invasive diagnostics**

Gastrointestinal – Calprotectin HD for enhancing diagnostic power

IBD* DIAGNOSIS – AS IS

- **Diagnosis complexity:** differentiation from diseases with similar presentation but with higher prevalence (IBD vs. IBS**)
- **Global prevalence:** ~230 per 100,000 people
- **Global incidence:** ~10 per 100,000 people-years
- ~ 7 mln people worldwide live with **IBD**, of which 3.2 mln in the U.S. (source CDC)



THE CHALLENGE

- **Limited specificity** (“grey zone”): Moderate calprotectin elevations are not disease-specific
- **Limited decision value:** Low specificity prevents calprotectin from reliably guiding decisions
- **Residual need for colonoscopy:** In grey-zone cases, colonoscopy remains the only available diagnostic option for clinicians



THE SOLUTION



Calprotectin HD

- **Combining Calprotectin with a novel biomarker** (MMP-8 metalloproteinase)
- Enhance assay **specificity** without compromising **sensitivity**
- **Accelerate diagnosis time** supporting for endoscopies prioritization


Calprotectin HD turns calprotectin from a screening marker into a decision-making tool, reducing unnecessary procedures and lowering healthcare burden

Uniquely available to Diasorin through patent protection

* Inflammatory Bowel Disease

** Irritable Bowel Syndrome

Gastrointestinal - Stool and Blood biomarkers inform IBD management across patient journey



5 key phases of the patient journey with IBD:

- Diagnosis
- Prediction of treatment response
- Assessment of disease activity
- Assessment of mucosal healing
- Prediction of relapse



Hypertension



Hypertension – a new guideline for primary Aldosteronism Including Diasorin established cutoffs



Primary Aldosteronism (PA): current market scenario

Severely underdiagnosed form of Hypertension: only 0.5-2% of total diagnosed population are tested for Aldosteronism

PA affects

- ~6% of **total hypertensive patients** in primary care
- ~30% of patients with **resistant hypertension**
- ~1-2% of **adult population worldwide**
- ~5-14% of **all hypertensive patients globally**

PA remains substantially underdiagnosed



The opportunity: a changing clinical environment



- **New 2025 guidelines** recommend universal screening for **Primary Aldosteronism** in all individuals diagnosed with hypertension
- **Screening recommended** through measurement of plasma aldosterone concentration, plasma renin concentration or activity, and the aldosterone-to-renin ratio (ARR)
- **2025 guidelines represent a major shift** towards universal screening and systematic management of primary aldosteronism



Hypertension – a new guideline for primary Aldosteronism Including Diasorin established cutoffs




DIASORIN LEADING THE WAY



- Recommended cut-off for ARR reflects **Diasorin's Aldosterone and Direct Renin ones**
- **LIAISON Aldosterone and LIAISON Direct Renin tests** are a reliable, accurate and simple to use method **for determining ARR**
- Seek FDA and IVDR specific approval for **ARR screening intended use and purpose**

TOTAL ACCESSIBLE MARKET (TAM)



- **Full adoption on new Guidelines could increase TAM to ~50M screening tests/year in Europe, US and Australia (25x growth vs today)**
- Historical data from similar guideline drive market changes shows **6-8x market size growth**

New guidelines creating a significant opportunity for LIAISON Aldosterone and LIAISON Direct Renin assays testing

MeMed





Memed – Target and initiatives 2026-2030 (US focus)

2026-2030

NEW CUSTOMERS ~50 per year

by 2030

TOTAL CUSTOMERS TARGET >250 = 1/3 of Diasorin’s U.S. Hospital Targets

What enables MeMed opportunity to grow initiatives

- Jupiter study**
 - MeMed BV guidance **reduced unnecessary antibiotic prescriptions** in viral patients **by 52% (25% vs 12%)**
 - Improved identification of bacterial infections with increased appropriate** antibiotic treatment (**41% → 78%**)
 - No increase in return ED visits** or hospitalization
 - Supports antibiotic stewardship** and optimized clinical decision-making
- Unbundling from DRG**
 - CMS unbundling request submitted** to enable separate reimbursement vs bundled payments
 - If approved, unlocks **fee-for-service model** and improves hospital adoption economics
- Private reimbursement**
 - Dossiers submitted to multiple US payers**; ongoing advisory boards and appeal support
 - Expected **progressive coverage expansion** across national/regional plans and IDNs

SYSTEMS

LIAISON XL Evolution

TODAY



LIAISON® X

H1'27



LIAISON® XL

Compact size. Expanded power. Fully Integrated.

- Maximum flexibility in every configuration
- Expanded capacity without increasing footprint
- Immediate access to a complete reagent menu
- Full compatibility with existing Total Lab Automation ecosystem
- Fewer steps, more walk-away time

Increased Sample Capacity and Accelerated workflow



Automated ID & De-capping



Smart tube handling



Optimized workflow & connectivity



Flexible installation



No Buffer Preparation Need

Improved Walk-away time, safety and workflow efficiency



diluteX



Automated

Throughput improvement up to 50%

Walkaway time minimum of 10 hours

U.S. HOSPITALS STRATEGY

U.S. Hospitals Strategy

TOTAL HOSPITALS

~150

NEW HOSPITALS

Identification of 2,200 hospitals (Addressable market)



START 2019



PHASE 1 2020-2022

~300

+150



PHASE 2 2023-2026

~600

+300



PHASE 3 2027-2030

~900

+300

Continue penetration and focus on add-on specialties

Diasorin continues to gain market share in the hospital segment with target of serving ~40% of US hospitals by 2030

FUTURE OPPORTUNITIES

Autoimmunity



Autoimmunity market

Specialty Autoimmune testing

Presenting the best opportunity for expansion in an untapped area of Immunodiagnostic testing



Size and competition

Global market¹:
~ 1.3 €/bn

~45% high-volume;
~55% specialty

Global specialty market¹:
~ 750 €/mln

~63% in Europe and NA, with **4 established specialty players**



Growth Driver

Reimbursement

Consistent global high single digit growth,
reaching **10%+** for some specialty areas

¹ 2025 data

Autoimmunity – Diasorin positioning

Autoimmunity testing is evolving from a niche specialty area into a **core component of centralized laboratory workflows**



Existing major **Total Lab Automation (TLA) suppliers** to Core Labs **do not offer** autoimmunity solutions



Diasorin recognized by leading TLA players as a complementary solution

~25% of LIAISON installed base already connected to laboratory automation tracks



Building a comprehensive autoimmunity panel creates a natural fit with major TLA platforms. By connecting LIAISON systems to automation tracks, autoimmunity becomes a high-value complementary segment within Core labs

Complementary Diagnostics



Diagnostics are no longer support – they are the decision

PRECISION MEDICINE | STRATEGIC CONTEXT

Precision medicine (companion and complementary diagnostics) is redefining how drugs reach patients—and how every clinical dollar is justified

COMPANION DIAGNOSTIC (CDx)

- Central to personalising drug treatment
- Provides information essential for safe & effective use of the therapy
- The test is required by the drug's Indications for Use

COMPLEMENTARY DIAGNOSTIC (ComDx)

- FDA-defined (mid-2015): identifies patients who respond particularly well to a drug
- Aids risk/benefit assessment—but is not a prerequisite for receiving the drug
- Not required by Indications for Use — but may be mentioned in drug labelling

Source: FDA Drug Approvals 2025; ClinicalTrials.gov pipeline analysis; IQVIA Institute 2025

40%

of all FDA drug approvals in 2025 are precision medicine / biomarker-driven

2 in 3

late-stage pipeline drugs are biomarker-driven in clinical development

70%


of the most advanced clinical decisions rely on diagnostic results to guide treatment

Diagnostic testing is no longer optional - it is the gateway to treatment

Half the precision medicine wave lies outside oncology – and we have the first proof points to act on it

STRATEGIC OPPORTUNITY | NON-ONCOLOGY EXPANSION

Precision medicine is mainstream in oncology—but 50% of biomarker-driven drugs already target other therapeutic areas, signaling the next frontier.



■ Oncology ■ Non-Oncology



HYPERTENSION – Primary aldosteronism and Aldo. Synthase Inhibitors (ASIs)
Biomarker and drug's response
Volume potential 6-10M tests/year



Anti-TNF-α - biologic drugs that block tumor necrosis factor-alpha (TNF-α)

+ Additional areas: GLP-1 agonists, Diabetes, Obesity, Chronic Inflammatory Diseases, Thyroid, bone-mineral, adrenal, etc.

Testing is a critical spend gateway—winning in non-oncology diagnostics means influencing the next generation of treatment pathways

Key Takeaways on Immunodiagnosics

Immunodiagnosics as a high-quality, innovation-driven growth platform, combining

- exposure to structural healthcare trends,
- sustainable competitive advantages with 20+ new products launching by 2030,
- significant long-term optionality in high-value adjacencies — anchored by a clear U.S. hospital penetration roadmap and the emerging role of diagnostics as the operating system of personalized medicine.

Strong positioning in large/attractive market

Strategic exposure
Focused portfolio targeting high-value segments

Differentiated competitive positioning/menu leadership

Broadest immunoassay menus in the market
Clear edge in high-value specialty testing

Clear execution

Across different key products:

- **Latent TB** global leadership,
- **Gastrointestinal** transition toward an integrated, patient-centric ecosystem,
- **Hypertension** guideline-driven upside,
- **MeMed** clinical evidence and reimbursement progress supporting adoption

Innovation-led growth

Tangible pipeline delivery
Continued pipeline execution reinforcing differentiation

Technology/systems as structural enabler

New LIAISON XL improving throughput, automation & TLA integration

Visible long-term growth optionality

2 key main projects: i) Autoimmunity and ii) Complementary diagnostics & precision medicine

Acceleration of U.S. hospital strategy

Clear penetration roadmap through a model focused on high-value specialties

04

MOLECULAR DIAGNOSTICS

Angelo Rago

President,
Luminex

Giulia Amicarelli

VP, Global Molecular Marketing
& Marketing Services

Macro trends in Healthcare: impact on Molecular Diagnostics

DRIVERS

Healthcare Pressures

- Aging populations & rising chronic disease burden
- Value-based care, spending pressure
- Workforce shortages: clinicians, nurses, lab staff
- Care decentralization, lab to Point of Care migration

NEEDS

Market Dynamics

- Increased demand for complex diagnosis, targeted to the patient
- Diagnostic stewardship, clinically appropriate testing at optimized cost
- Simplicity, automation, flexibility across settings
- Speed at point of decision, data-driven integrated platforms


WINNING PROFILE

What Will Win

- Targeted and highly specialized testing
- Flexible and customizable diagnostics, tailored to the needs
- Automated, streamlined operation, implementation and support
- Fast diagnostics, connected, with analytics built in

Diasorin's Molecular Strategy is designed to deliver answers to the evolving needs in healthcare

Molecular ID Diagnostics requires technologies specific to the needs




Diasorin is leading the way in Diagnostic Stewardship

Diasorin is executing on the Strategy to provide the right test for the right patient in the right setting.

We believe in the value of the technologies specialized to the market segment needs


Molecular ID Diagnostics requires technologies specific to the needs



USA represents 45% of the Global Market

Integrated Delivery Networks and where ID diagnostics is performed


A vertical system integrated by EMR, quality metrics, and payers' contracts



More complicated cases are diagnosed in highly specialized Hospital Laboratories, while less acute episodes can be managed decentralized

Integrated Delivery Networks and physicians' acquisition

A vertical system integrated by EMR, quality metrics, and payers' contracts



IDNs are focused on capturing and keeping patients within their network

Decentralized (CLIA-waived) segment: \$1.5B Opportunity

90% of testing is Respiratory



10K

30K


183K

Acute

~4M tests

Non-Acute

~26M tests



~\$1.5B

~30M tests

Kalorama; Expert interview; Bain analysis

* CLIA database

10% CAGR driven by decentralization and shift from antigen to molecular


Diasorin Portfolio positioning



Diasorin portfolio positioning, in the IDN evolving landscape

To win in IDN accounts, our diagnostic platform must be enablers of their objectives.

IDNs are evolving their view of diagnostics from cost centers to levers for downstream savings and outcome improvement



LIAISON NES



LIAISON NES is designed to fit the Point-of-Care segment

- ✓ ~15 min Time to Result
- ✓ Highly automated
- ✓ Enhanced connectivity
- ✓ Streamlined implementation
- ✓ Touchscreen
- ✓ Room temperature storage

Consumer-like approach tailored to the segment



ASSAY MENU

FDA-Cleared Menu

LIAISON NES
FLU A/B, RSV & COVID-19



In-Development Menu

LIAISON NES
Group A Strep*
Submitted to the FDA and currently in review



LIAISON NES
STI panel
In development



*Pending FDA clearance

LIAISON NES is enabling simplicity by focusing on user needs

3-step workflow
(Room temperature reagents)

~15-minute time to result
(**<1 min hands-on time**)

Multiplex assay
(Flu A, Flu B, RSV, COVID-19)



Seamless connectivity

(Wi-Fi/ethernet, laboratory information system LIS, cloud)

Lab-quality performance

Using real-time RT-PCR (reverse transcription polymerase chain reaction) technology

Portable & compact

(4.3 in. W x 10.2 in. L x 9.5 in. H)

We designed a system custom-built for the point-of-care segment.
A medical device with a consumer-like approach

LIAISON NES is enabling simplicity by focusing on user needs


	BENCH SPACE FRONT WIDTH	PORTABLE DIMS & WEIGHTS	STORAGE	STEPS TO SET-UP A TEST	AMPLIFICATION TIME	MULTIPLEXING	VISUALIZE CTS AND PCR CURVES
LIAISON NES Launched in 2026	11.5 cm 4.5 in	Y 3 kgs, 6.6 lbs.	Room Temp	7	16.5 min	4 targets +IC	Y
COMPETITORS Launched in 2015-2023	11.5-30 cm 11.5 in	Y/N ~18 -34 kgs	RT- Refrigerated	Up to 28	15-30 min	1 target up to 5 targets	N

LIAISON NES differentiates for combining fast and accurate performance with a streamlined usability that simplifies operations and reduces barriers to adoption



LIAISON NES Go-To-Market

Leveraging Direct Sales force and Distribution



Commercial execution via the multiplier force of distribution

The Critical Gap in Sexually Transmitted Infections and Women's Health

STI diagnostics remain lab-dependent; clinicians cannot act during the patient visit

THE PROBLEMS

Hours to Days

Results from centralized labs arrive too late for same-visit treatment decisions

Patients Lost

High-volume clinics lose patients to follow-up before treatment begins

Empiric Overtreatment

Clinicians over-prescribe antibiotics without etiologic diagnosis

DIMENSION OF THE PROBLEMS

2.5M+ Annual STI Cases

Chlamydia, gonorrhea, and trichomoniasis remain the most reported US infections

10M Vaginitis Visits/Yr

Most common gynecologic complaint

14K+ Decentralized Sites

OB-GYN, STI clinics, urgent care, primary care all underserved by current POC tools

THE OPPORTUNITY




LIAISON NES can close the gap

Delivering rapid, CLIA-waived molecular results, enabling same-visit treatment:

- ✓ Immediate targeted treatment
- ✓ Avoidance of unnecessary antibiotics
- ✓ Patient counseling & partner notification
- ✓ Clinical decision before procedures

Future Potential Market Opportunity

Limited product availability today, mostly represented by highly centralized testing



Out of ~ 1 \$/bn Women's Health & STI Diagnostic TAM by 2030,
POC molecular market is **~200 \$/mln, growing at +15% CAGR**

LIAISON PLEX



The right test for the right patient: LIAISON PLEX

- ✓ Flex Testing
- ✓ Random access
- ✓ Sample-to-answer workflow
- ✓ Scalable
- ✓ Touchscreen interface
- ✓ Room temperature storage



ASSAY MENU

FDA-Cleared Menu



LIAISON PLEX Respiratory *Flex* Assay



LIAISON PLEX Gram-Positive Blood Culture Assay



LIAISON PLEX Gram-Negative Blood Culture Assay



LIAISON PLEX Yeast Blood Culture Assay



LIAISON PLEX Gastrointestinal *Flex* Assay


In-Development Menu



LIAISON PLEX ME *Flex* Assay*

* currently under development.

Syndromic Technologies Portfolio Assessment, USA




US Syndromic Multiplex Diagnostics Market
2026 estimate

~1.2 \$/bn
U.S. TAM

~5%
CAGR

Traditional syndromic testing is under pressure




Financial and Reimbursement Challenges
 Shifting reimbursement models, tighter budgets, and policy uncertainty require every test to demonstrate clear clinical and economic impact.

Diagnostic Overuse and Stewardship Pressures
 Expectations for accurate, timely diagnostics without over-testing are on the rise.

Evolving Workforce
 As laboratory staffing availability decreases, sustainable solutions must simplify processes without compromising accuracy.


Diasorin's Differentiation

Competition Vendor Defined Fixed Panels



- ✓ Broad coverage for immunocompromised and high-acuity inpatients
- ✗ One-size-fits-all increases unnecessary testing
- ✗ Not aligned with clinical guidance
- ✗ Less control on cost burden to hospital and patient

Diasorin LIAISON PLEX Patient Focused Flexible Panels



- ✓ Actionable results focused on higher probability pathogens
- ✓ Aligned with clinical guideline recommendations for clinical context
- ✓ Improved cost control and alignment with reimbursement

Intentional testing for better outcomes

Customizable panel selection aligned with clinical guidelines and patient presentation

Example of LIAISON PLEX RSP Flex at a Primary U.S. Hospital System



Respiratory Pathogen PCR Panel

- ADENOVIRUS (A,B,C,D,E,F)
- CORONAVIRUS (HKU1, NL63, OC43, 229E)
- ENTEROVIRUS/RHINOVIRUS
- HUMAN METAPNEUMOVIRUS
- INFLUENZA A
- INFLUENZA B
- PARAINFLUENZA 1
- PARAINFLUENZA 2
- PARAINFLUENZA 3
- PARAINFLUENZA 4
- RESPIRATORY SYNCYTIAL VIRUS (A&B)
- SARS-COV-2
- BORDETELLA HOLMESII
- BORDETELLA PARAPERTUSSIS
- BORDETELLA PERTUSSIS
- CHLAMYDIA PNEUMONIAE
- MYCOPLASMA PNEUMONIAE




Respiratory Pathogen PCR Panel (w/o COVID/FLU/RSV)

- ADENOVIRUS (A,B,C,D,E,F)
- CORONAVIRUS (HKU1, NL63, OC43, 229E)
- ENTEROVIRUS/RHINOVIRUS
- HUMAN METAPNEUMOVIRUS
- PARAINFLUENZA 1
- PARAINFLUENZA 2
- PARAINFLUENZA 3
- PARAINFLUENZA 4
- BORDETELLA HOLMESII
- BORDETELLA PARAPERTUSSIS (IS1001)
- BORDETELLA PERTUSSIN (TOXIN PROMOTER)
- CHLAMYDIA PNEUMONIAE
- MYCOPLASMA PNEUMONIAE




FLU/RSV/SARS-CoV-2/Rhinovirus PCR

- ENTEROVIRUS/RHINOVIRUS
- INFLUENZA A
- INFLUENZA B
- RESPIRATORY SYNCYTIAL VIRUS (A&B)
- SARS-COV-2



Bordetella PCR

- BORDETELLA HOLMESII
- BORDETELLA PARAPERTUSSIS
- BORDETELLA PERTUSSIN



Mycoplasma & Chlamydia Pneumoniae PCR

- CHLAMYDIA PNEUMONIAE
- MYCOPLASMA PNEUMONIAE

Adopted customized panels that enable diagnostic stewardship by aligning provider needs with optimized respiratory testing across seven sites

Example of Gastrointestinal Syndromic testing based on Clinical Need

Community Acquired Diarrhea

- Norovirus
- Salmonella spp.
- Campylobacter spp.
- STEC stx1
- STEC stx2
- Rotavirus
- Shigella/EIEC
- Adenovirus
- Giardia lamblia

Hospital Acquired infections

- Norovirus
- *C. difficile*
- Rotavirus
- STEC *stx1*
- STEC *stx2*
- *Salmonella* spp.
- Shigella/EIEC
- *Campylobacter* spp.
- *Cryptosporidium* spp.

Immuno-compromised

- Norovirus
- Salmonella spp.
- *C. difficile*
- *Cryptosporidium* spp.
- Giardia lamblia
- *Campylobacter* spp.
- Adenovirus
- Shigella/EIEC
- STEC stx1
- (STEC stx2)

Outbreak Investigations

- Norovirus
- Salmonella spp.
- STEC stx1
- STEC stx2
- Rotavirus
- *Campylobacter* spp.
- Shigella/EIEC
- *Cryptosporidium* spp.
- Adenovirus

Travel

- Norovirus
- *Campylobacter* spp.
- Salmonella spp.
- ETEC LT/ST
- STEC stx1
- STEC stx2
- Giardia lamblia
- Shigella/EIEC
- Rotavirus

Pediatric

- Rotavirus
- *Salmonella* spp.
- Norovirus
- STEC *stx2*
- STEC *stx1*
- *Campylobacter* spp.
- Adenovirus
- Shigella/EIEC
- Giardia lamblia

Routine/General

- *Campylobacter* spp.
- Norovirus
- *Salmonella* spp.
- *C. difficile*
- STEC *stx1*
- STEC *stx2*
- Giardia lamblia
- Rotavirus
- Shigella/EIEC

Foodborne Illness

- *Salmonella* spp.
- Norovirus
- STEC *stx1*
- STEC *stx2*
- Shigella/EIEC
- *Campylobacter* spp.
- Giardia lamblia
- Rotavirus
- *Cryptosporidium* spp.

LIAISON PLEX GI Flex consists of 24 pathogens that can be combined to fit specific clinical needs

Gastrointestinal - Why the coverage gap exists

It is not about number of targets: the pathogens chosen determine clinical reach


Legend: ● Bacteria ● Viruses ● Parasites

Competitor 1 11 targets



- *Campylobacter* spp
- *C. difficile*
- *Salmonella*
- *Shigella*/EIEC
- STEC stx1/stx2
- *Vibrio* spp
- *Yersinia*
- Norovirus
- *Cryptosporidium* sp
- *Cyclospora*
- *Giardia lamblia*

Competitor 2 11 targets



- *Campylobacter* spp
- *Salmonella*
- *Shigella*/EIEC
- STEC stx1
- STEC stx2
- *Vibrio cholerae*
- *Vibrio* spp
- *Yersinia*
- Norovirus
- *Cryptosporidium* sp
- *Giardia lamblia*

LIAISON PLEX GI Flex Choose 11 targets



Customer selects targets from a 24-pathogen menu, tailored to the clinical case mix.

- | | |
|-----------------------------|--------------------------|
| ● <i>Campylobacter</i> spp | ● <i>C. difficile</i> |
| ● ETEC | ● <i>Plesiomonas</i> |
| ● <i>Salmonella</i> | ● <i>Shigella</i> /EIEC |
| ● STEC stx1 | ● STEC stx2 |
| ● <i>Vibrio cholerae</i> | ● <i>Vibrio</i> spp |
| ● <i>Yersinia</i> | ● Norovirus |
| ● Rotavirus | ● Adenovirus F40/41 |
| ● Astrovirus | ● Sapovirus |
| ● <i>Cryptosporidium</i> sp | ● <i>Giardia lamblia</i> |
| ● <i>Cyclospora</i> | ● <i>E. histolytica</i> |
| ● <i>Blastocystis</i> | ● <i>Dientamoeba</i> |
| ● Microsporidia | ● <i>Strongyloides</i> |

WHY THIS MATTERS — composition gaps explain coverage shortfalls

HAI: Competitor 2 omits *C. difficile*. Pediatric: Competitors omit Rotavirus or Adenovirus.

Flexibility and Customization maximize effectiveness



VOLUME-WEIGHTED COVERAGE


Across all 8 clinical scenarios, weighted by avg weekly volume

- LIAISON PLEX (Base 11) **73%**
- Competitor 1 (11) **33%**
- Competitor 2 (11) **10%**


THE COVERAGE FOOTPRINT

- **LIAISON PLEX:** balanced footprint covering all 8 scenarios — clinically broad
- **Competitor 1:** adequate on bacterial-heavy scenarios (Routine/HAI/Foodborne) but limited on viral/parasitic load (Pediatric/Travel/Outbreak)
- **Competitor 2:** Foodborne reaches a usable level (40%); fails clinically on every other scenario

Diagnostic stewardship



Diasorin's Solution



LIAISON NES and LIAISON PLEX RSP Flex are substantially equivalent as per the study outcome reported in the 510(k) FDA clearance

The LIAISON NES + LIAISON PLEX solution increases efficiency, reduces repeated, redundant testing and its cost

LIAISON MDX Plus*



* Launch in H1'27

LIAISON MDX and MDX Plus

- ✓ Sample-to-answer
- ✓ Scalable
- ✓ CLIA moderate
- ✓ IVD and Open mode capabilities
- ✓ Differentiated Menu
- ✓ No need for extraction

ASSAY MENU

FDA- cleared Menu



Simplexa HSV1&2 Direct



Simplexa VZV Swab Direct

Simplexa VZV CSF Direct

Simplexa COVID-19, FluA/B and RSV Direct



Simplexa COVID-19, FluA/B Direct

Simplexa FluA/B and RSV Direct

Simplexa COVID-19



Simplexa Bordetella Direct

Simplexa cCMV Direct

Simplexa *C auris* Direct


Simplexa GAS Direct

Simplexa GBS Direct

Simplexa *C difficile* Direct




Targeted Technologies Market Size, USA



US Target Diagnostics Market 2026 estimate

~5.1 \$/bn




US TAM



The success of the “specialty product strategy” on LIAISON MDX


Acute, complicated cases needs high-clinical value diagnostics that drive patient management. Diasorin expertise in specialty testing confirms its positioning in the marketplace

Revenue growth of unique, De-Novo LIAISON MDX applications



Mid-to-high single digits CAGR on specialty targeted tests + new specialty tests to be launched

Diasorin will continue to expand in Specialty Testing



Emerging clinical areas where the Diasorin technologies can close a gap with specialty testing

Annual Cases of Lyme Disease in the US

Critical group	High group	Medium group
<i>Cryptococcus neoformans</i>	<i>Neisseria meningitidis</i>	<i>Scedosporium spp.</i>
<i>Candida auris</i>	<i>Histoplasma spp.</i>	<i>Lomentospora prolificans</i>
<i>Aspergillus fumigatus</i>	Eumycetozoa causative agents	<i>Coccidioides spp.</i>
<i>Candida albicans</i>	Mucorales	<i>Pichia kudriavzevii (Candida krusei)</i>
	<i>Fusarium spp.</i>	<i>Cryptococcus gattii</i>
	<i>Candida tropicalis</i>	<i>Talaromyces marneffii</i>
	<i>Candida parapsilosis</i>	<i>Pneumocystis jirovecii</i>
		<i>Paracoccidioides spp.</i>

WHO fungal priority pathogens list

FUNGAL PATHOGENS THAT ARE 'BECOMING A THREAT TO HUMANITY'

Cryptococcus neoformans
can cause deadly brain infections. Globally, it is a major cause of illness in patients with HIV/AIDS and kills at least 180,000 people annually.


Aspergillus
produce spores that spread in the air and can threaten the lung health of people with compromised immune systems.

Candida albicans
is commonly found in the gut but could cause invasive infections in immunocompromised people. It can cause an asthma-like illness, pulmonary fibrosis or a non-cancerous tumor.

Candida auris
which grows on yeast, leads to severe and numerous deadly infections. The mortality rate of the fungus, which spreads quickly in healthcare settings, can be as high as 60%.

Diasorin portfolio positioning in the IDN evolving landscape

Key Takeaways on Molecular Diagnostics



- Diasorin is executing on the Strategy to provide the right test for the right patient in the right setting
- Diasorin is leader in syndromic customized testing
- Technologies tailored to the different segments' needs, without compromises
- The combination of technologies creates value through more comprehensive solutions
- We are *Diagnostic Specialist* in Molecular

The Diasorin's strategy in Molecular Diagnostics is aligned with the market evolving landscape, leading the way in enabling Diagnostic Stewardship

05

LICENSED TECHNOLOGIES

Angelo Rago


President Luminex

Licensed Technologies: Enabling Innovation & Value Creation

2025 LTG Revenue & Segments

Life Science Research

- Basic Research
- Applied Research



Pharma


- Drug Discovery
- Vaccines Development



Diagnostics

- Transplant
- Autoimmune
- Infectious Diseases

>80% Recurring Revenue



Diagnostics

Diasorin serves diagnostic partners that create specialty applications

- Transplant diagnostics
- Autoimmune & ID Diagnostics
- Testing services (biomarker LDTs)

Diagnostic segment is a stable and profitable business, growing at market rate



TAM
1.4 €/bn; 6% CAGR

- ~40% penetration
- Transplant diagnostics (~ 90%)
 - Autoimmune & ID Diagnostics (40%)
 - Testing services (biomarker LDTs) (10%)

Products

Diagnostic Kits

Transplant

Autoimmune

Multi-pathogen

IVD Instruments

OEM Modules



Partners & Customers

Major Partners

End-Users



Commercial Labs
Hospitals
Transplant Centers

Life Science Research

Diasorin serves Life Science partners who provide ready-to-use multi-analyte panels to power pharma discovery and academic research

1,300+ partner developed multi-plex kits available globally



TAM
535 €/mln | 6% CAGR

~30% penetration

Products

Research Use Only Kits

Quantitative Proteomics

Preconfigured Panels



Gene Expression

Mix & Match



Biomarker Panels

Single Target Kits



RUO Instruments



Automation



Partners & Customers

Major Partners



End-Users

Academia
Pharma Discovery
Applied Research

Pharma

Diasorin enables pharmaceutical companies to develop specialty and proprietary assays for drug and vaccine development

xMAP in Specialty Vaccine Clinical Trials



Supporting Phase III Clinical Studies with Project AdVance



Drug Discovery TAM
2.4 €/bn | 5% CAGR

Vaccines TAM
300 €/mln | 9% CAGR

Products

RUO Kits & Ingredients for GLP Assays

Drug Discovery

Multivalent Vaccines

Assay Kits



Microspheres



Assay Support Svc



RUO Instruments



INTELLIFLEX Magpix LX200

Automation



inSPIRE Platform

Partners & Customers

Major Partners



Direct Sales



Key Takeaways on Licensed Technologies

Revenue base

Highly recurring and high-quality

Diversified business model

Diagnostics, Life Science Research and Pharma

Exposure to multiple end-markets

- **Diagnostics:** stable and profitable core (growth in line with the market)
- **Life Science & Pharma:** innovation-driven growth engines, supporting research, drug discovery and vaccine development

Strong partner ecosystem and embedded positioning

Long-term, sticky relationships and royalty streams

A resilient, partner-driven business delivering recurring revenues and long-term growth optionality

Attractive market fundamentals across segments

Solid TAMs and growth profiles

Scalable platform with multiple monetization levers

Kits, consumables, instruments, and royalties

06

ESG & FINANCIALS

Alberto Donati

CFO

ESG



ESG 2026-2030

OBJECTIVES

KPIs

E



Improve Group's energy efficiency

-600 tons of CO₂ in industrial sites by 2030

S



Strengthen Diversity & Inclusion

100% of employees trained on D&I

Enhance employee wellbeing

≥80% of Group employees covered by employee assistance programs

Promote scientific culture in high schools

5 €/mln investment over 2026-2030 to Fondazione Diasorin

Support women's health and autoimmune diseases diagnosis

> 20 high clinical value assays validated by 2030

G




Strengthen ESG governance

ESG-linked remuneration targets for strategic executives

FINANCIALS


Guidance @CER*: Total Revenues



* In order to allow comparability across years, all financials' data have been restated at constant exchange rate (with regard to the U.S. dollar 1.20 USD per EUR)

Revenues By Technology @CER*


- Licensed Technologies
- Molecular Diagnostics
- Immunodiagnosics



* In order to allow comparability across years, all financials' data have been restated at constant exchange rate (with regard to the U.S. dollar 1.20 USD per EUR)

Revenues By Geography @CER*

- Rest of the World
- Europe
- North America




* In order to allow comparability across years, all financials' data have been restated at constant exchange rate (with regard to the U.S. dollar 1.20 USD per EUR)


Revenues Evolution: from 2026 to 2030

BY TECHNOLOGY

2026




2030




BY GEOGRAPHY

2026




2030



All percentages are rounded

Guidance @CER*: Adjusted** EBITDA Margin and Free-Cash-Flow

Adjusted EBITDA Margin



* In order to allow comparability across years, all financials' data have been restated at constant exchange rate (with regard to the U.S. dollar 1.20 USD per EUR)

** Excluding non-recurring integration / restructuring costs

Cumulated FCF*** over 4 years (2027-2030)

~ 1 €/bn

***FCF defined as Reported EBITDA, less Net Working Capital absorptions, cash taxes paid and capital expenditures

Strong Operating Cash Flow Generation and Disciplined Capital Deployment to Maximise Shareholder Value

Capital Deployment Supported by Strong Cash Flow Generation

- 1 Organic Growth**
Continue investing in the business in support of long-term organic growth
- 2 Dividends**
Committed to delivering attractive shareholder returns
- 3 Targeted M&A**
Disciplined bolt-on acquisitions to accelerate our strategic roadmap
- 4 Share Buy-back**
Selectively as part of a balanced shareholder returns framework

	FY 23-26	FY 27-30
	<i>Investment Amount / % of Total</i>	<i>% of Total</i>
1 Organic Growth	~500 €/mIn ~40%	~35%
2 Dividends	~250 €/mIn ~20%	~20%
3 Targeted M&A		Selective
4 Share Buy-back	~300 €/mIn ~25%	Opportunistic

...while continuing de-leverage

Operating Cash Flow defined as Reported EBITDA, less Net Working Capital absorption and cash taxes paid

07

KEY TAKEAWAYS

Carlo Rosa

CEO

Looking Forward to 2030: what do we commit to deliver

Immunodiagnosics

>20 new assays to cover
Autoimmunity, GI and ID specialties

New LIAISON XL with enhanced
features for high-throughput
customers

Leverage on automation and
competitive advantage in TB market
to maintain market leadership

Launch of 1 Companion Diagnostic
product

Molecular Diagnostics

Increasing competitiveness of LIAISON
NES, expanding in women's health

Complete the LIAISON PLEX table
stake panels, adding
Meningitis/Encephalitis on top of the
existing RSP, Blood and GI panels

Launch of a new generation platform,
LIAISON MDX Plus, supporting our
specialty portfolio

Licensed Technologies

Increasing revenue opportunity through
new contracts with Diagnostic and
Biopharma partners

Stabilization of sales to customers
linked to Academia

Leveraging proprietary technology to
drive scalable licensing, royalties and
long-term recurring revenue streams

Leveraging automation and AI in Operations to expand margins

Commercial geographical expansion in key countries

Optimizing R&D spending and installed base investments

08 Q&A

Carlo Rosa
CEO

Alberto Donati
CFO



Diasorin